Taylor Group

Dr Carme Camps


Post-doctoral researcher


Wellcome Trust Centre for Human Genetics, Roosevelt Dr.
Oxford, OX3 7BN


Work summary

My current research within the Oxford BRC is focused on the clinical applications of next generation sequencing. I am involved in the development and testing of two gene panels that are based on Ampliseq technology and Ion Torrent PGM sequencing (Life Technologies). One of the panels is aimed to detect genetic variations in the coding and UTR regions of 21 genes that are either known to be or potentially causative for familial erythrocytosis. The other gene panel is part of a Technology Strategy Board programme on tumour profiling. The 148 genes included in this panel were selected based on their high mutation rate and therapeutic value in cancer. This would enable the referral of patients to targeted treatments or suitable clinical trials according to their tumour type.

Previously, I acquired experience on transcriptomics while conducting research under the supervision of Dr. Jiannis Ragoussis during his time at the WTCHG. I used a wide range of techniques including RNA-seq, microRNA-seq and ChIP-seq to perform a comprehensive study on the regulation of microRNA expression under hypoxia in the breast cancer cell line MCF-7. Furthermore, microRNA and gene expression profiling of a series of breast cancer tumours allowed the detection of microRNAs as independent prognostic factors and their association with key pathways.

I am also teaching at the Wellcome Trust Advanced Course “Functional Genomics and Systems Biology”, an international laboratory course for postgraduate researchers based at the Wellcome Trust Sanger Institute. 

Publications with the Oxford BRC:

Cazier JB, Rao SR, McLean CM, Walker AL, Wright BJ, Jaeger EE, Kartsonaki C, Marsden L, Yau C, Camps C, Kaisaki P; Oxford-Illumina WGS500 Consortium, Taylor J, Catto JW, Tomlinson IP, Kiltie AE, Hamdy FC.Whole-genome sequencing of bladder cancers reveals somatic CDKN1A mutations and clinicopathological associations with mutation burden. Nat Commun. (2014) Apr 29;5:3756. PMID: 24777035

Key previous publications:

Camps C, Saini HK, Mole DR, Choudhry H, Reczko M, Guerra-Assunção JA, Tian YM, Buffa FM, Harris AL, Hatzigeorgiou AG, Enright AJ, Ragoussis J. Integrated analysis of microRNA and mRNA expression and association with HIF binding reveals the complexity of microRNA expression regulation under hypoxia. Mol Cancer. (2014) Feb 11;13:28. PMID: 24517586

Buffa FM, Camps C, Winchester L, Snell CE, Gee HE, Sheldon H, Taylor M, Harris AL, Ragoussis J. microRNA-associated progression pathways and potential therapeutic targets identified by integrated mRNA and microRNA expression profiling in breast cancer. Cancer Res. (2011) Sep 1;71(17):5635-45. Epub 2011 Jul 7. PMID: 21737487

Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, Harris AL, Gleadle JM, Ragoussis J. hsa-miR-210 Is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res. (2008) Mar 1;14(5):1340-8. doi: 10.1158/1078-0432.CCR-07-1755. PMID: 18316553 [PubMed - indexed for MEDLINE]